双磷酸盐——历史记录、治疗和协议

C. Bacci, B. Emanuele, M. Favero
{"title":"双磷酸盐——历史记录、治疗和协议","authors":"C. Bacci,&nbsp;B. Emanuele,&nbsp;M. Favero","doi":"10.1016/j.ios.2011.01.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>For years bisphosphonates have been used to treat osteopenic disorders and breast and prostate cancer. Along with their therapeutic effects, these drugs have also significant collateral effects, and their use has been associated with osteomyelitis and osteonecrosis of the jaw (ONJ). Dentists need to be familiar with this disorder since it involves the orofacial region. The purpose of this article is to provide an overview of bisphosphonates, their mechanism of action and their therapeutic applications. We also review guidelines for dentists on the prevention and management of ONJ.</p></div><div><h3>Materials and methods</h3><p>We reviewed articles published in English between 1999 and 2009 whose titles included the following terms: “osteonecrosis of the jaw”, “bisphosphonate”, “alendronate”, “pamidronate”, or “zolendronate”. The review included case reports of bisphosphonate-associated ONJ in adults. The data reported included patient age, sex, and medical and dental history, as well as characteristics of the bisphosphonate treatment (drug used, dose, route of administration, duration of treatment).</p></div><div><h3>Results</h3><p>Our research revealed that the most common site of bisphosphonate-associated osteonecrosis is the mandible, followed by the maxilla. Most patients were women &gt;50 years of age, and 80% of the patients had undergone dental surgery at the site of the ONJ. There was no clear correlation between the duration of bisphosphonate treatment and the development of ONJ.</p></div><div><h3>Conclusions</h3><p>Millions of patients are receiving bisphosphonates for the treatment of osteoporosis, and ONJ is one of the most common complications observed in such patients. The typical patient with ONJ is a female, &gt;50 years of age, with a history of dental surgery or trauma. Dentists play a primary role in the treatment of ONJ associated with the use of bisphosphonates. However, definitive conclusions on the causal relation between oral bisphosphonate use and ONJ are not possible at this time because these drugs are still being investigated and the results emerging from different studies are sometimes discordant.</p></div>","PeriodicalId":100732,"journal":{"name":"Italian Oral Surgery","volume":"11 1","pages":"Pages 28-36"},"PeriodicalIF":0.0000,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ios.2011.01.003","citationCount":"0","resultStr":"{\"title\":\"Bifosfonati: note storiche, terapie e protocolli\",\"authors\":\"C. Bacci,&nbsp;B. Emanuele,&nbsp;M. Favero\",\"doi\":\"10.1016/j.ios.2011.01.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>For years bisphosphonates have been used to treat osteopenic disorders and breast and prostate cancer. Along with their therapeutic effects, these drugs have also significant collateral effects, and their use has been associated with osteomyelitis and osteonecrosis of the jaw (ONJ). Dentists need to be familiar with this disorder since it involves the orofacial region. The purpose of this article is to provide an overview of bisphosphonates, their mechanism of action and their therapeutic applications. We also review guidelines for dentists on the prevention and management of ONJ.</p></div><div><h3>Materials and methods</h3><p>We reviewed articles published in English between 1999 and 2009 whose titles included the following terms: “osteonecrosis of the jaw”, “bisphosphonate”, “alendronate”, “pamidronate”, or “zolendronate”. The review included case reports of bisphosphonate-associated ONJ in adults. The data reported included patient age, sex, and medical and dental history, as well as characteristics of the bisphosphonate treatment (drug used, dose, route of administration, duration of treatment).</p></div><div><h3>Results</h3><p>Our research revealed that the most common site of bisphosphonate-associated osteonecrosis is the mandible, followed by the maxilla. Most patients were women &gt;50 years of age, and 80% of the patients had undergone dental surgery at the site of the ONJ. There was no clear correlation between the duration of bisphosphonate treatment and the development of ONJ.</p></div><div><h3>Conclusions</h3><p>Millions of patients are receiving bisphosphonates for the treatment of osteoporosis, and ONJ is one of the most common complications observed in such patients. The typical patient with ONJ is a female, &gt;50 years of age, with a history of dental surgery or trauma. Dentists play a primary role in the treatment of ONJ associated with the use of bisphosphonates. However, definitive conclusions on the causal relation between oral bisphosphonate use and ONJ are not possible at this time because these drugs are still being investigated and the results emerging from different studies are sometimes discordant.</p></div>\",\"PeriodicalId\":100732,\"journal\":{\"name\":\"Italian Oral Surgery\",\"volume\":\"11 1\",\"pages\":\"Pages 28-36\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ios.2011.01.003\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Italian Oral Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1827245211000043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian Oral Surgery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1827245211000043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

多年来,双膦酸盐一直用于治疗骨质减少症、乳腺癌和前列腺癌。除了治疗效果外,这些药物也有显著的副作用,它们的使用与颌骨骨髓炎和骨坏死有关(ONJ)。牙医需要熟悉这种疾病,因为它涉及到口腔面部区域。本文的目的是提供概述双膦酸盐,他们的作用机制和他们的治疗应用。我们还审查了牙医预防和管理ONJ的指南。材料和方法我们回顾了1999年至2009年间发表的英文文章,其标题包括以下术语:“颌骨骨坏死”、“双膦酸盐”、“阿仑膦酸盐”、“帕米膦酸盐”或“唑仑膦酸盐”。该综述包括成人双膦酸盐相关的ONJ病例报告。报告的数据包括患者的年龄、性别、病史和牙科病史,以及双膦酸盐治疗的特点(使用的药物、剂量、给药途径、治疗持续时间)。结果双膦酸盐相关性骨坏死最常见的部位是下颌骨,其次是上颌骨。大多数患者是50岁的女性,80%的患者在ONJ部位做过牙科手术。双膦酸盐治疗的持续时间与ONJ的发生没有明显的相关性。结论数百万患者正在接受双膦酸盐治疗骨质疏松症,而ONJ是这类患者最常见的并发症之一。ONJ的典型患者为女性,50岁,有牙科手术或外伤史。牙医在治疗与使用双膦酸盐相关的ONJ中起主要作用。然而,由于口服双膦酸盐与ONJ之间的因果关系仍在研究中,不同研究的结果有时不一致,因此目前尚无法得出明确的结论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Bifosfonati: note storiche, terapie e protocolli

Introduction

For years bisphosphonates have been used to treat osteopenic disorders and breast and prostate cancer. Along with their therapeutic effects, these drugs have also significant collateral effects, and their use has been associated with osteomyelitis and osteonecrosis of the jaw (ONJ). Dentists need to be familiar with this disorder since it involves the orofacial region. The purpose of this article is to provide an overview of bisphosphonates, their mechanism of action and their therapeutic applications. We also review guidelines for dentists on the prevention and management of ONJ.

Materials and methods

We reviewed articles published in English between 1999 and 2009 whose titles included the following terms: “osteonecrosis of the jaw”, “bisphosphonate”, “alendronate”, “pamidronate”, or “zolendronate”. The review included case reports of bisphosphonate-associated ONJ in adults. The data reported included patient age, sex, and medical and dental history, as well as characteristics of the bisphosphonate treatment (drug used, dose, route of administration, duration of treatment).

Results

Our research revealed that the most common site of bisphosphonate-associated osteonecrosis is the mandible, followed by the maxilla. Most patients were women >50 years of age, and 80% of the patients had undergone dental surgery at the site of the ONJ. There was no clear correlation between the duration of bisphosphonate treatment and the development of ONJ.

Conclusions

Millions of patients are receiving bisphosphonates for the treatment of osteoporosis, and ONJ is one of the most common complications observed in such patients. The typical patient with ONJ is a female, >50 years of age, with a history of dental surgery or trauma. Dentists play a primary role in the treatment of ONJ associated with the use of bisphosphonates. However, definitive conclusions on the causal relation between oral bisphosphonate use and ONJ are not possible at this time because these drugs are still being investigated and the results emerging from different studies are sometimes discordant.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信